Literature DB >> 17112813

Warfarin dose requirement for patients with both VKORC1 3673A/A and CYP2C9*3/*3 genotypes.

Tsuyoshi Fukuda, Tomoko Tanabe, Masako Ohno, Katsuhiko Tougou, Yasushi Fujio, Junichi Azuma, Isamu Yamamoto, Akira Takeda.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 17112813     DOI： 10.1016/j.clpt.2006.08.005

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN： 0009-9236            Impact factor:   6.875


× No keyword cloud information.
  3 in total

1.  Influence of clinical and genetic factors on warfarin dose requirements among Japanese patients.

Authors:  Masako Ohno; Akiko Yamamoto; Ayumu Ono; Genta Miura; Masanobu Funamoto; Yasuhiko Takemoto; Kinya Otsu; Yasushi Kouno; Tomoko Tanabe; Yuiko Masunaga; Shinpei Nonen; Yasushi Fujio; Junichi Azuma
Journal:  Eur J Clin Pharmacol       Date:  2009-07-07       Impact factor: 2.953

2.  Warfarin Dosing in a Patient with CYP2C9(∗)3(∗)3 and VKORC1-1639 AA Genotypes.

Authors:  Mark Johnson; Craig Richard; Renee Bogdan; Robert Kidd
Journal:  Case Rep Genet       Date:  2014-01-22

Review 3.  Influence of CYP2C9 and VKORC1 on patient response to warfarin: a systematic review and meta-analysis.

Authors:  Andrea L Jorgensen; Richard J FitzGerald; James Oyee; Munir Pirmohamed; Paula R Williamson
Journal:  PLoS One       Date:  2012-08-29       Impact factor: 3.240
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.